Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.

ABSTRACT A growing number of jurisdictions now request economic data in support of their decision-making procedures for the pricing and/or reimbursement of health technologies. Because more jurisdictions request economic data, the burden on study sponsors and researchers increases. There are many reasons why the cost-effectiveness of health technologies might vary from place to place. Therefore, this report of an ISPOR Good Practices Task Force reviews what national guidelines for economic evaluation say about transferability, discusses which elements of data could potentially vary from place to place, and recommends good research practices for dealing with aspects of transferability, including strategies based on the analysis of individual patient data and based on decision-analytic modeling.

[1]  A. Levy,et al.  The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  S. Pocock,et al.  The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial , 2007, Heart.

[3]  Mark Oppe,et al.  EQ-5D Value Sets , 2007 .

[4]  Richard Willke,et al.  Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  M. A. Best.  Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .

[6]  Andrew R Willan,et al.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. , 2006, PharmacoEconomics.

[7]  R. Grieve,et al.  Using multilevel models for assessing the variability of multinational resource use and cost data. , 2005, Health economics.

[8]  John K Kruschke,et al.  Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.

[9]  J Hjelmgren,et al.  Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  D. Spiegelhalter,et al.  Bayesian Approaches to Clinical Trials and Health-Care Evaluation: Spiegelhalter/Clinical Trials and Health-Care Evaluation , 2004 .

[11]  Mark Oppe,et al.  EQ-5D value sets : inventory, comparative review, and user guide , 2007 .

[12]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[13]  Peter C Smith,et al.  Health Policy and Economics: Opportunities and Challenges , 2004 .

[14]  Nigel Rice,et al.  Cost-Effectiveness Analysis Using Data from Multinational Trials: The Use of Bivariate Hierarchical Modeling , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  P. Kind,et al.  A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  M. Drummond,et al.  What do international pharmacoeconomic guidelines say about economic data transferability? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  B. O'brien,et al.  Cost–effectiveness analysis for multinational clinical trials , 2005, Statistics in medicine.

[18]  M. Sculpher,et al.  It ’ s Just Evaluation for Decision Making : Recent Developments in , and Challenges for , Cost-Effectiveness Research , 2003 .

[19]  G. Brown,et al.  Analysis of costs. , 2000, Archives of ophthalmology.

[20]  R. Willke,et al.  Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, Health economics.

[21]  Simon G Thompson,et al.  Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.

[22]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[23]  A. Tsuchiya,et al.  A comparison of EQ-5D time trade-off values obtained in Germany, The United Kingdom and Spain , 2003 .

[24]  M. Gail,et al.  Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.

[25]  M A Koopmanschap,et al.  Analysis of costs and cost-effectiveness in multinational trials. , 2001, Health policy.

[26]  F. Pang,et al.  Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.

[27]  D. DeMets,et al.  Statistical issues relating to international differences in clinical trials. , 2001, American heart journal.

[28]  Michael Drummond,et al.  Assessing the appropriateness of combining economic data from multinational clinical trials , 2003, Statistics in medicine.

[29]  W. Busse,et al.  Cost‐effectiveness of asthma control: an economic appraisal of the GOAL study , 2006, Allergy.

[30]  Frank de Charro,et al.  The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective , 2003, Springer Netherlands.

[31]  R. Robinson.  Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .

[32]  C Duncan,et al.  Health-related behaviour in context: a multilevel modelling approach. , 1996, Social science & medicine.

[33]  Mark J Sculpher,et al.  Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? , 2006, PharmacoEconomics.

[34]  John Cairns,et al.  Multilevel models for estimating incremental net benefits in multinational studies. , 2007, Health economics.

[35]  Laura Ginnelly,et al.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? , 2005, International journal of cardiology.

[36]  B. O'brien,et al.  Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. , 2005, Health economics.

[37]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[38]  M. Sculpher,et al.  Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. , 2005, Health economics.

[39]  Andrew M. Jones,et al.  Multilevel models and health economics. , 1997, Health economics.

[40]  Richard Grieve,et al.  Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. , 2006, Journal of health economics.